摘要
目的:观察ATRA联合As2O3治疗初发和复发的急性早幼粒细胞白血病(APL)患者的疗效和不良反应。方法:ATRA 25 mg/(m2.d)分3次口服,联合0.1%As2O3,0.16 mg/(kg.d)静脉滴注治疗,直至CR。根据外周血白细胞计数,维甲酸综合征以及肝功能变化调整ATRA和As2O3的剂量。结果:364例患者中,初治者CR率92.5%,复治者CR率75%,取得CR平均时间分别为28.8 d和33.9 d。早期病死率4.7%。联合用药的毒副作用并未增加。结论:ATRA联合As2O3治疗疗效好,达CR时间短,不良反应少。
Objective： To observe the efficacy and side effects of all-trans retinoic acid（ATRA）combined with arsenic trioxide （As2O3）on remission induction in newly-diagnosed and relapsed patients with acute promyeloeytie leukemia（APL）. Methods： Three hundred and sixty four patients were treated with ATRA orally 25 mg/（m^2 · d） every day（in three separate doses）and As203 （0. 16 mg/（kg · d） for intravenous drop once a day until complete remission（CR）. The doses were adjusted according to white blood eell（WBC）counts,occurrence of RA syndrome and the status of live function. Results：There were 329 of the 364 patients achieved CR （92. 5%）in newly-diagnesed patients,while CR rate was 75% in relapsed patients. The average time for achieving CR in the two groups was 28.8 day and 33.9 day, respectively. The early death was 4. 7%. The combined use did not further enhance toxic side effects. Conclusion： The combination of ATRA and As2O3 in the treatment of APL can obtain a higher CR rate without intolerable side effects and a shorter duration for achieving CR.
出处
《实用临床医学（江西）》
CAS
2006年第6期37-39,共3页
Practical Clinical Medicine
关键词
维甲酸
砷剂
白血病
早幼粒细胞
急性
retinoic acid
arsenicals
leukemia, promyelocytic, acute
